Hemostemix Receives FDA Support for Basket Protocol Approach in Stem Cell Therapy Development
核心洞察
Hemostemix successfully completed its pre-IND meeting with the FDA on January 16, 2026, receiving guidance that its basket protocol approach is acceptable for evaluating ACP-01 across multiple ischemic conditions.
The FDA provided support for the company's real-world evidence collection plan in jurisdictions including Florida, Canada, and The Bahamas, structured to meet FDA publication standards.
The basket protocol will evaluate ACP-01 treatment across vascular dementia (搜索), ischemic cardiomyopathy (搜索), peripheral arterial disease (搜索), and generalized ischemia under a unified ischemia-based mechanism.
Hemostemix Inc (搜索). has received positive guidance from the U.S. Food and Drug Administration (FDA) following its pre-Investigational New Drug (pre-IND) meeting on January 16, 2026, marking a significant regulatory milestone for the company's autologous stem cell therapy platform. The FDA indicated that Hemostemix's basket protocol approach is acceptable for advancing its ACP-01 treatment across multiple ischemic conditions.
FDA Endorses Basket Protocol Strategy
The FDA provided guidance confirming that Hemostemix's basket protocol approach is acceptable, subject to specific requirements including clearly defined eligibility criteria, appropriate handling of patient heterogeneity, and rigorous clinical and statistical design. The basket protocol is designed to evaluate ACP-01 across multiple ischemic and vascular-related conditions that share common underlying pathophysiology, while maintaining clinically meaningful cohort definitions and appropriate analytical methods.
The protocol will address four key ischemic conditions under a single mechanism of action:
- Vascular dementia
- Ischemic cardiomyopathy
- Peripheral arterial disease (PAD)
- Generalized ischemia
"The FDA's guidance supports Hemostemix' basket protocol strategy, and collection of RWE, enabling the Company to advance across multiple ischemic diseases," stated Thomas Smeenk, CEO. "We are incorporating the FDA's feedback in our IND submission, data models and statistical analyses of patients treated with ACP-01."
Real-World Evidence Collection Approved
The company also received FDA guidance supporting its plan to capture ACP-01 real-world data in jurisdictions including Florida, Canada, and The Bahamas. The guidance supports the collection of real-world evidence (RWE) structured in a manner consistent with FDA publications, addressing patient privacy, safety and data integrity requirements.
Clinical Track Record and Outcomes
Hemostemix has established a substantial clinical foundation for ACP-01, having completed seven clinical studies involving 318 subjects and published results in eleven peer-reviewed publications. The company reports that ACP-01 has demonstrated safety, clinical relevance and statistical significance as a treatment for peripheral arterial disease (搜索), chronic limb threatening ischemia (搜索), non-ischemic dilated cardiomyopathy (搜索), ischemic cardiomyopathy (搜索), congestive heart failure (搜索), and angina (搜索).
Notably, the company completed its Phase II clinical trial for chronic limb threatening ischemia (搜索) and published results in the Journal of Biomedical Research & Environmental Science. In a significant clinical outcome comparison, while the chronic limb threatening ischemia (CLTI) patient population typically faces a five-year mortality rate of 50%, UBC and University of Toronto reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, and wound healing in 83% of patients followed for up to 4.5 years as a midpoint result.
Expert Team and Next Steps
Hemostemix's FDA meeting team included CEO Thomas Smeenk, Chief Scientific Officer Dr. Ina Sarel, Chief Medical Officer Dr. Fraser Henderson (Professor of Neurosurgery and practicing neurosurgeon), Dr. Ernst von Schwarz (triple board-certified transplant surgeon, cardiologist and stem cell researcher), and Dr. William Shankle (neurologist specializing in vascular dementia (搜索) and Alzheimer's prevention, diagnosis, and management).
The company is now proceeding with filing its IND submission, including product comparison validation studies. Hemostemix has indicated it will provide updates throughout the regulatory process.
Technology Platform
Founded in 2003 and recognized as a World Economic Forum Technology Pioneer Award winner, Hemostemix has developed and patented VesCell (搜索)™ (ACP-01), an autologous blood-based stem cell therapy. The treatment utilizes patients' own stem cells and is currently being offered to individuals suffering from various ischemic conditions at Doctors Hospital in Nassau, The Bahamas, as well as in Florida and Canada.